Replies to post #198683 on Biotech Values

[DewDiligence]

…ABBV decided stay away from other HCV GT groups.

Actually, the phase-3 program for ABT-493/ABT-530 is testing all genotypes—see the next post—so I presume you meant to say that the head-to-head trial against Sovaldi/Daklinza is only for GT3 patients. That’s true but unrevealing insofar as GT3 is the only genotype where the Sovaldi/Daklinza combination is likely to be used.